Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012

1. Introduction: From Mystery Matrix Proteins to Precise Molecular Actions in Human Disease - p. 42 2. A New Take on Uptake: Dopamine Transporters & the Cellular Mechanisms of Amphetamine Action - p. 43 3. A Retrospective on PET and the Amphetamine Paradigm: Validation and Paradoxes - p. 44 4. The Corelease of Glutamate by Dopamine Neurons - p. 45 5. Psychostimulant-Induced Alterations of Monoaminergic Transporters: Implications for Neurotoxicity and Neuroprotection - p. 46 6. Trace Amine Associated Receptor 1 is a Catecholamine Receptor that Differentially Controls DAT and NET Internalization - p. 47 7. VGF-Derived Peptide TLQP-21: Structure, Function, and Biomedical Implications - p. 48 8. Chromogranins the Key Proteins for the Storage and Regulation of Exocytosis in Chromaffin Cells - p. 49 9. Chromogranin A in the Storage and Exocytosis of Catecholamines - p. 50 10. The Involvement of Vesicular ATP in the Storage and Exocytosis of Catecholamines of Bovine Chromaffin Cells - p. 51 11. The Role of Ca2+ Release from the Endoplasmic Reticulum in the Catecholamine Hypersecretion of Adrenal Chromaffin Cells from Spontaneously Hypertensive Rats - p. 52 12. PACAP as a Primary Effector of the Acute Sympatho-Adrenal Stress Response - p. 53 13. Amphetamine Induced Dopamine Release in Macaque Monkeys: Striking Differences Between Prefrontal Cortex and Caudate Nucleus - p. 55 14. Attenuated Amphetamine-Induced Dopamine Release in Subjects at Ultra-High Risk for Substance Dependence - p. 56 15. The Membrane-Raft Protein Flotillin-1 is Essential in Dopamine Neurons for Amphetamine-Induced Behavior in Drosophila - p. 57 16. Plant Flavonoids Affecting Adrenal Medullary Catecholamine Biosynthesis and Release - p. 58 17. A Protein Complex for Dopamine Synthesis and Vesicular Storage: Target for Cellular Oxidative Damage - p. 59 18. Overexpression of Parkin in The Nigrostriatal System Might Protect Dopaminergic Terminals From Methamphetamine Neurotoxicity Via Regulation of Dopamine Transporter - p. 60 19. Increased Catecholamine Toxicity in Mice with Low Expression of VMAT2 - p. 61 20. Theme C: Metabolism - p. 62 21. Theme C Metabolism - p. 62 22. Renalase: A New Player in Catecholamine Metabolism - p. 64 23. Abnormal Monoamine Oxidase A VT in the Prefrontal and Anterior Cingulate Cortex During Major Depressive Episodes and High Risk States for Major Depressive Episodes - p. 65 24. CNS Catecholamine Metabolism – Emerging Concepts - p. 66 25. Catestatin (Human Chromogranin A352-372) Induces Lipolysis and Fatty Acid Oxidation through Regulation of Adrenergic and Leptin Signaling - p. 67 26. Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models - p. 69 27. Understanding Catecholamine Metabolism as a Guide for Assessment of Sympathoadrenal Function and Dysfunction in Health and Disease - p. 70 28. Multiplex Immunoassay for Catecholamines - p. 71 29. Modifiers of Neurofibromatosis-Associated Tumors and the Potential Role for Catecholamines and Sex Differences - p. 72 30. Catecholamine Metabolism in Chromogranins Knock-Out Mice - p. 73 31. Translation Research in Autism and Cancer: Novel Roles of MAO - p. 74 32. COMT is a Major Contributor to Pain Perception: from Humans to Rats and Back to Humans - p. 76 33. Novel COMT Inhibitors in Parkinson Disease - p. 77 34. Effect of Opicapone, a New Catechol-O-Methyltransferase Inhibitor, in Levodopa Pharmakokinetics in the Cynomolgous Monkey - p. 78 35. Does Impaired Aldehyde Detoxification Play a Role in Parkinson’s Disease? - p. 79 36. The Role of Aldehyde Detoxification in Parkinson’s Disease - p. 80 37. Pharmacological Profile of Opicapone in Wistar rat - p. 82 38. Theme D: Catecholamine Receptors and Catecholaminergic Signaling - p. 83 39. Theme D Catecholamine Receptors and Catecholaminergic Signaling - p. 83 40. How Drugs Bind and Control their Targets: Characterizing GPCR Signaling through Long-Timescale Simulation - p. 86 41. Structural basis of Subtype Selectivity in Dopamine D3 and D2 Receptors - p. 86 42. Hormone-Mediated Activation of G Proteins by GPCRs: Insights from the Crystal Structure of a GPCR-G Protein Complex - p. 88 43. Towards Better Understanding of G(s) Coupling in Catecholamine Receptors - p. 88 44. Receptor Heteromerization: Understanding the Functional and Pathological Role of the Dopamine D4 Receptor - p. 90 45. Trace Amines and Their Receptors: New Opportunities for Modulation of Brain Dopaminergic Functions - p. 91 46. Cross-Talk between G Protein-Coupled Receptors: Challenges of Distinguishing Upstream from Downstream Mechanisms - p. 92 47. Growth Hormone Secretagogue Receptor (GHSR1a, aka Ghrelin Receptor) is an Allosteric Modulator of Dopamine Signaling in the Brain via Formation of GHSR1a:DRD2 and GHSR1a:DRD1 Heteromers - p. 93 48. Regulation of β2Adrenergic Receptor Trafficking and Signaling by Ubiquitination and Deubiquitination - p. 94 49. Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling - p. 95 50. Trafficking of the D2 Dopamine Receptor Promotes Drug-Induced Changes in Neuronal and Behavioral Plasticity - p. 96 51. D2 Receptors Control of Dopamine Levels - p. 97 52. Integrated Approaches to Understand the Actions of GPCRs: The b-Arrestin-Dependent D2R Mediated Signaling Through Akt/GSK3 - p. 98 53. Hyperdopaminergic Modulation of Inhibitory Transmission is Dependent on GSK-3β Signaling-Mediated Trafficking of GABAA Receptors - p. 99 54. Simultaneous, Massively Parallel and Genome-Wide Interrogation of GPCR b-arrestin-ergic Signaling: Implications for GPCR Drug Discovery and Catecholamine Biology - p. 100 55. Backwards and Forwards with Molecular and Classical Pharmacology - p. 101 56. Targeting Beta-Arrestin Dependent Signaling in the Treatment of Parkinson’s Disease - p. 102 57. D2 Functionally Selective Ligands: novel Therapeutics? - p. 104 58. Investigation of the D1-D2 heteromer: pharmacology, subunit composition, and mechanisms of signaling - p. 105 59. β-Adrenergic Receptors, Caveolae and Caveolins: Receptor Localization and Function - p. 106 60. Protein Kinase C β and the Dopamine Transporter Influence Surface D2-Like Dopamine Receptor Localization - p. 107 61. Role of Adrenaline on the Maturation of β2-Adrenoceptors - p. 108 62. Deciphering the Functionally Selective Properties of D2R Ligands - p. 109 63. Chronic loss of Noradrenergic Tone Produces β-Arrestin2-Mediated Cocaine Hypersensitivity and a GαI to Gαs switch in D2 Receptor Coupling in the Nucleus Accumbens - p. 110 64. Probing the Functional Selectivity of β-adrenergic Receptors Reveals New Signaling Modes and Potential Therapeutic Applications - p. 111 65. Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor - p. 112 66. Novel cAMP Sensor Links GPCR-Gs Signaling to ERK in Neuroscreen-1 Cells - p. 113 67. High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes - p. 114 68. Discovery and Characterization of TAAR1 Agonists, Modulators of Dopaminergic and Serotonergic Neurotransmission with Therapeutic Potential in Neuropsychiatric Disorders - p. 115 69. Theme E: Neurology - p. 116 70. Theme E Neurology - p. 116 71. Modeling Parkinson’s Disease in a Mouse Model Overexpressing Astrocytic Monoamine Oxidase B (MAO-B): Towards Exploring Novel Therapeutics - p. 119 72. 3,4-Dihydroxyphenylacetaldehyde is an Autotoxic and Protein-Reactive Intermediate of Dopamine Catabolism - p. 120 73. Dopamine Oxidation and Quinone Modification of Proteins: Mechanisms of Toxicity and Implications for Parkinson’s Disease - p. 121 74. Insights into LRRK2-Mutation Related PD from PET Imaging Studies - p. 122 75. Norepinephrine Deficiency in Parkinson Disease - p. 123 76. Progressive Noradrenergic Degeneration in Mice with Reduced Expression of the Vesicular Monoamine Transporter (VMAT2) - p. 124 77. LRRK2 and Risk of PD - p. 125 78. Synuclein-Mitochondrial Interactions in Substantia Nigra Dopamine Neurons - p. 125 79. Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson’s Disease - p. 127 80. Induction of Chaperone-Mediated Autophagy as a Means to Attenuate Alpha-Synuclein-Mediated Neurotoxicity - p. 128 81. The Link between Neuronal Phenotype and Vulnerability in Parkinson’s Disease - p. 129 82. Willie Sutton’s Getaway Car and the Pathogenesis of Parkinson Disease - p. 130 83. Contributions of Dopamine in the Dorsal Striatum to Behaviors Corresponding to Cognitive Dysfunction in Parkinson’s Disease - p. 131 84. Cardiac Sympathetic Denervation: A Biomarker of Lewy Body Diseases - p. 132 85. Cerebrospinal Fluid Biomarkers of Central Catecholamine Deficiency in Parkinson Disease and Other Synucleinopathies - p. 133 86. Comparison Between Myocardial Sympathetic and Striatal Dopaminergic Imaging in Lewy Body Diseases: “Union is strength!” - p. 134 87. A Role For Neuronal MHC-I Display in Parkinson’s Disease? - p. 135 88. Modeling of Preclinical and Clinical Stages of Parkinsonism in MPTP-treated Mice with Focus on Tyrosine Hydroxylase in Survived Nigrostriatal Dopaminergic Neurons - p. 136 89. Role of Multiple Factors in Susceptibility of Neurons in Parkinson’s Disease - p. 137 90. Modeling of Presymptomatic and Symptomatic Stages of Parkinsonism in MPTP-treated Mice: Extra-nigrostriatal Manifestations - p. 138 91. Basal and Graded 6-OHDA –induced Differences in Striatal Dopamine and its Metabolites in two Mouse Lines with A30P–Mutated Alpha-Synuclein - p. 139 92. Rasagiline Reduces Striatal Dopamine Release and Extracellular Oxidative Stress in a Rat Model of Early Parkinson’s Disease - p. 140 93. Approach Towards Development of Multifunctional Drugs As an Effective Strategy for Treatment of Parkinson’s Disease - p. 141 94. Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models - p. 143 95. Theme F: Psychiatry and Psychology - p. 144 96. Theme F Psychiatry and Psychology - p. 144 97. Rewarding Dopamine - p. 147 98. Modulating Local Circuit Dynamics versus Long-Range Inputs - p. 147 99. Midbrain Dopamine Neurons are Divided into Different Functional Groups - p. 148 100. Dopamine System Dysregulation by the Hippocampus and the Pathophysiology of Schizophrenia - p. 149 101. The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia: In Vivo Evidence from the Prodrome to the First Psychotic Episode - p. 150 102. Striatal Dopamine Release in Schizophrenia Comorbis with Substance Dependence - p. 151 103. Neuroimaging Studies of Central Catecholaminergic Function in Depression - p. 152 104. Central and Peripheral Norepinephrine Secretion in Major Depression is Activated, as Assessed by 24 hour CSF and Plasma Sampling - p. 153 105. Norepinephrine: A Broken Spoke on the Wheel of Depression - p. 154 106. PET Imaging of Serotonin Transmission in Monkeys: Effects of Maternal Separation and Long-Term Fluoxetine Treatment during Adolescence - p. 156 107. Opposing Regulation of Norepinephrine and Dopamine in Rat Limbic Brain Regions in Response to Aversive Stimuli - p. 158 108. The Locus Coeruleus, Stress, Opioids and Behavioral Flexibility - p. 159 109. Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis - p. 160 110. Evaluation of [11C]ORM-13070 as a PET tracer for α2C-adrenoceptors in the human brain - p. 161 111. Theme G: Drug Abuse and Addiction - p. 162 112. Theme G Drug Abuse and Addiction - p. 162 113. Addiction: Story of an Unbalanced Brain - p. 165 114. Essential Catecholamine Influences on Dorsolateral Prefrontal Cortical Cognitive Function: Molecular Signaling Pathways - p. 165 115. Neural Mechanisms Underlying the Cognition-Enhancing Actions of Pyschostimulants: Relevance to ADHD - p. 167 116. Frontostriatal Systems and Differential Roles of Dopamine D1- and D2-Like Receptors in Impulsivity and Response Inhibition - p. 168 117. Catecholamine Strategies for Remediating Fronto-Executive Deficits in Stimulant Addiction and Related Disorders - p. 170 118. Ultrastructural and Optogenetic Evidence for Dual Neuronal Signaling by Dopamine Neurons of the Ventral Tegmental Area (VTA) - p. 171 119. Seeking reward: Upstream modulation of VTA dopamine neurons by orexin/hypocretin inputs - p. 172 120. Striatal Dopamine, Self-control and Decision-Making: Identifying Therapeutic Targets for Addiction through Brain Imaging - p. 173 121. Imaging Neurochemical Transmission in Substance Abuse: Commonalities and Differences Across Addictions - p. 175 122. Dopamine Transmission in Cocaine Addiction: Linking the Animal and Human Studies - p. 176 123. Growth Associated Protein-43, Amphetamine and Dopamine Transporter Activity - p. 176 124. The Role of Ion Binding in Transporter Conformational Transition - p. 178 125. Evidence for the Contribution of D4 Receptors to Cocaine Self-Administration in Monkeys - p. 179 126. Drug Design for Addiction – Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor - p. 180 127. Cue-Induced Dopamine Release in Striatal and Extra-striatal Regions in Cocaine Dependent Users: A High Resolution PET [18F]Fallypride Study - p. 182 128. β-arrestin Regulation of Ghrelin Signaling in modulating Addictive Behavior - p. 183 129. Dopamine D3 and D4 Receptors as Therapeutic Targets for Nicotine Addiction - p. 184 130. Long-Term Cocaine Exposure Affects Dopamine D3 Receptor Function - p. 185 131. Theme H: Catecholamines in the Periphery - p. 186 132. Theme H Catecholamines in the Periphery - p. 186 133. Recurrent Hypoglycemic Stress Differentially Regulates Catecholamine Release and Transmitter Gene Expression - p. 189 134. Sympathetic Mechanism of Hypertension - p. 190 135. Harnessing the Autonomic System for Therapeutic Intervention - p. 191 136. Norepinephrine Transporter Function and Human Cardiovascular Regulation - p. 192 137. Role of Common Genetic Variation in Control of Human Adrenergic Function and Blood Pressure: Focus on the Chromogranins - p. 193 138. What is the Optimal Biochemical Diagnostic Strategy for Pheochromocytoma? - p. 194 139. SDHx-Related Pheochromocytoms: New Advances in Genetics and Functional Imaging - p. 195 140. Novel Methods Peripheral Autonomic Assessment - p. 196 141. Identification and Functional Characterization of Genetic Variants of the Catecholamine Release-Inhibitory Peptide Catestatin in an Indian Population - p. 197 142. The Osmopressor Response in Human Physiology - p. 198 143. Adrenergic Derived Myocardium: Anatomic Substrate for Stress Induced Cardiomyopathies - p. 200 144. The Relationship of Norepinephrine to Stress Induced Hypertension - p. 201 145. Regulation of Adrenal Phenylethanolamine N-methyltransferase Gene Expression and Adrenaline Synthesis in a Fetal Programming Model of Hypertension - p. 202 146. Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland - p. 204 147. Effect of Daidzein on Mean Arterial Pressure and Vascular Dysfunction in CLP-Induced Septic Mice - p. 205 148. Adrenal-Specific G Protein-Coupled Receptor Kinase (GRK)-2 Deficiency Reduces Circulating Catecholamine Levels and Improves Cardiac Function after Myocardial Infarction - p. 206 149. Serotonin and Catecholamines In Regulation of Myocardium Functions in Children with Congenital Heart Diseases - p. 207 150. “Genetic and Acquired Determinants of Postural Tachycardia Syndrome” - p. 208 151. Neurotransmitter dopamine regulates tumor growth - p. 209 152. Extra Virgin Olive Oil Increases Uncoupling Protein 1 Content in Brown Adipose Tissue and Enhances Noradrenaline and Adrenaline Secretions in Rats - p. 210 153. Neurovisceral Integration and Regulation of Peripheral Indices of ANS Function - p. 211 154. Theme I: Catecholamines in Integrative Function - p. 212 155. Theme I Catecholamines in Integrative Function - p. 212 156. Neuropeptide Y Infusion to Rats Attenuates Development of PTSD-Like Symptoms to Traumatic Stress - p. 214 157. PTSD and the Locus Coeeurleus - p. 215 158. Systems Biology and the Stress Response: From Pythagoras and the Epicureans to Modern Medicine - p. 216 159. Reactive Oxygen Species and Neuropeptide Y Signaling in Altered Catecholamine Synthesis during Intermittent Hypoxia - p. 219 160. Stress, HIF1a, and Adrenergic Function - p. 220 161. Characterization of Cerebrospinal Fluid (CSF) and Plasma NPY Levels in Normal Volunteers over a 24-h Timeframe - p. 222 162. NPY: Low Cerebrospinal Fluid (CSF) Levels in Posttraumatic Stress Disorder in Comparison to Combat and Civilian, non-combat Control Subjects - p. 223 163. Developmental Neuroendocrinology of Posttraumatic Stress Disorder in Children and Adolescents after Motor Vehicle Accidents - p. 224 164. Repeated and Novel Stress-triggered Changes in Adipocyte Catecholamine System - p. 225 165. Jekyll and Hyde: Noradrenergic Modulation in Acute and Chronic Stress - p. 226 166. Early Life Stress Increases Nucleus Accumbens Dopamine Signaling - p. 228 167. Modulation of Inflammatory Cytokine Release by Hypoxia Mediated Tyrosine Hydroxylase Induction in Mixed Synovial Cells of Patients with Rheumatoid Arthritis and Osteoarthritis - p. 229 168. Theme J: Catecholamine Interactions with Other Transmitters - p. 231 169. Theme J Catecholamine Interactions with Other Transmitters - p. 231 170. Catecholamine Release Modulation by Adenosine through A2AReceptors in Mouse Chromaffin Cell Culture - p. 234 171. Morphological and Functional Significance of Coexistence of PACAP with Catecholamine in Nerve Terminals Innervating Hypothalamic Neuroendocrine Cells - p. 235 172. Interactions of Neuropeptide Y, Catecholamines and Angiotensin at the Vascular Neuroeffector Junction - p. 236 173. Overview: Neuropeptide-Catecholamine Interactions in Stress - p. 237 174. Neuropeptide Regulation of the Locus Coeruleus (LC) in the Mediation of Stress Responses - p. 237 175. Breaking Down Monoamine “Silos”: We’re all in this Together - p. 238 176. Orexin/hypocretin in the Ventral Tegmental Area is Necessary for Morphine-Induced Synaptic Plasticity of Dopamine Neurons - p. 239 177. The Adrenomedullary Angiotensin II Type 2 Receptor: Stress-Triggered Regulation and Role in Catecholamine Biosynthesis - p. 241 178. Angiotensin AT1 Receptor Blockade Prevents Excessive Brain and Peripheral Sympathetic Stimulation During Stress - p. 242 179. Catecholamine Release Modulation by Adenosine Through A2a Receptors in Mouse Chromaffin Cells in Culture - p. 243 180. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), A Master Regulator in Central and Peripheral Stress Responses - p. 245 181. Novel Catecholamine Mechanisms in Memory Consolidation and Retrieval During Stress - p. 246 182. Catecholaminergic Regulation of Peptide Synthesis and Release Programs in Paraventricular CRH Neurons - p. 247 183. Control of Dopamine Neurotransmission in the Prefrontal Cortex: Focus on Serotonin and Norepinephrine Systems - p. 248 184. Unfaithful Neurotransmitter Transporters: Focus on Biogenic Amine Reuptake and Implications for Antidepressant Efficacy - p. 249 185. L-DOPA and the Brain Pattern of Dopamine Extracellular Levels: a New Deal Imposed by Serotonergic and Noradrenergic Fibres - p. 250 186. Individual Differences in Nicotinic Acetylcholine Receptor Modulation of Dopamine Signals in the Nucleus Accumbens Shell - p. 251 187. Insulin Induces Long-term Depression in VTA DA Neurons via an Endocannabinoid-mediated Mechanism - p. 252